Black Creek Investment Management Inc. Decreases Position in Elanco Animal Health Incorporated $ELAN

Black Creek Investment Management Inc. lowered its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 12.7% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 19,250,840 shares of the company’s stock after selling 2,791,776 shares during the period. Elanco Animal Health comprises about 12.7% of Black Creek Investment Management Inc.’s portfolio, making the stock its biggest holding. Black Creek Investment Management Inc. owned about 3.87% of Elanco Animal Health worth $274,902,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of ELAN. MTM Investment Management LLC raised its stake in Elanco Animal Health by 5.5% during the second quarter. MTM Investment Management LLC now owns 15,268 shares of the company’s stock worth $218,000 after acquiring an additional 800 shares in the last quarter. HighTower Advisors LLC grew its holdings in shares of Elanco Animal Health by 7.0% during the 1st quarter. HighTower Advisors LLC now owns 12,445 shares of the company’s stock valued at $131,000 after purchasing an additional 810 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its position in Elanco Animal Health by 8.9% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 11,516 shares of the company’s stock worth $169,000 after purchasing an additional 944 shares in the last quarter. ProShare Advisors LLC lifted its stake in Elanco Animal Health by 8.7% in the 2nd quarter. ProShare Advisors LLC now owns 12,439 shares of the company’s stock valued at $178,000 after purchasing an additional 999 shares during the last quarter. Finally, Commerce Bank lifted its stake in Elanco Animal Health by 3.7% in the 1st quarter. Commerce Bank now owns 35,321 shares of the company’s stock valued at $371,000 after purchasing an additional 1,256 shares during the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

Elanco Animal Health Trading Up 1.6%

NYSE ELAN opened at $21.42 on Tuesday. The firm has a market capitalization of $10.64 billion, a PE ratio of 357.04, a price-to-earnings-growth ratio of 2.86 and a beta of 1.71. The business’s 50-day moving average price is $20.63 and its two-hundred day moving average price is $16.79. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $23.09.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same period in the previous year, the firm earned $0.13 earnings per share. The firm’s quarterly revenue was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. On average, analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Wall Street Analyst Weigh In

ELAN has been the topic of a number of research reports. Zacks Research cut shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 6th. Stifel Nicolaus boosted their price objective on Elanco Animal Health from $18.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Wall Street Zen raised Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Saturday. Piper Sandler lifted their price target on Elanco Animal Health from $12.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, August 11th. Finally, JPMorgan Chase & Co. upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $18.00 to $24.00 in a report on Tuesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Elanco Animal Health has an average rating of “Moderate Buy” and an average price target of $20.29.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.